122 related articles for article (PubMed ID: 34370601)
1. No Tumor Suppressor Role for
Koseoglu H; Celebi A; Galamiyeva G; Dalay N; Ozkardes H; Buyru N
DNA Cell Biol; 2021 Sep; 40(9):1222-1229. PubMed ID: 34370601
[TBL] [Abstract][Full Text] [Related]
2. p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer.
Schlechte H; Lenk SV; Löning T; Schnorr D; Rudolph BD; Ditscherlein G; Loening SA
Eur Urol; 1998; 34(5):433-40. PubMed ID: 9803007
[TBL] [Abstract][Full Text] [Related]
3. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
4. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
Zhong W; Peng J; He H; Wu D; Han Z; Bi X; Dai Q
Clin Invest Med; 2008; 31(1):E8-E15. PubMed ID: 18312749
[TBL] [Abstract][Full Text] [Related]
5. Expression of kallikrein-related peptidase 7 is decreased in prostate cancer.
Zhang CY; Zhu Y; Rui WB; Dai J; Shen ZJ
Asian J Androl; 2015; 17(1):106-10. PubMed ID: 25219913
[TBL] [Abstract][Full Text] [Related]
6. PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma.
Koch P; Petri M; Paradowska A; Stenzinger A; Sturm K; Steger K; Wimmer M
Prostate; 2009 Dec; 69(16):1751-62. PubMed ID: 19691131
[TBL] [Abstract][Full Text] [Related]
7. Low LKB1 Expression Results in Unfavorable Prognosis in Prostate Cancer Patients.
Lu J; Sun P; Sun B; Wang C
Med Sci Monit; 2015 Nov; 21():3722-7. PubMed ID: 26616116
[TBL] [Abstract][Full Text] [Related]
8. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
Su Z; Wang G; Li L
Cancer Biomark; 2023; 38(2):143-159. PubMed ID: 37781794
[TBL] [Abstract][Full Text] [Related]
9. Real-time quantitative RT-PCR assessment of PIM-1 and hK2 mRNA expression in benign prostate hyperplasia and prostate cancer.
He HC; Bi XC; Zheng ZW; Dai QS; Han ZD; Liang YX; Ye YK; Zeng GH; Zhu G; Zhong WD
Med Oncol; 2009; 26(3):303-8. PubMed ID: 19003546
[TBL] [Abstract][Full Text] [Related]
10. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma.
Cordon-Cardo C; Koff A; Drobnjak M; Capodieci P; Osman I; Millard SS; Gaudin PB; Fazzari M; Zhang ZF; Massague J; Scher HI
J Natl Cancer Inst; 1998 Sep; 90(17):1284-91. PubMed ID: 9731735
[TBL] [Abstract][Full Text] [Related]
11. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
12. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor of DNA binding-1 overexpression in prostate cancer: relevance to tumor differentiation.
Yu X; Xu X; Han B; Zhou R
Pathol Oncol Res; 2009 Mar; 15(1):91-6. PubMed ID: 18752043
[TBL] [Abstract][Full Text] [Related]
14. The prostate cancer immunome: In silico functional analysis of antigenic proteins from microarray profiling with IgG.
Luna-Coronell JA; Vierlinger K; Gamperl M; Hofbauer J; Berger I; Weinhäusel A
Proteomics; 2016 Apr; 16(8):1204-14. PubMed ID: 27089054
[TBL] [Abstract][Full Text] [Related]
15. [Expressions of the androgen receptor in normal prostate, benign prostatic hyperplasia and prostate cancer].
Zeng R; Liu ZY; Sun YH; Xu CL; Gao X; Jiao L
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):967-72. PubMed ID: 21218636
[TBL] [Abstract][Full Text] [Related]
16. Gene expression of Aurora kinases in prostate cancer and nodular hyperplasia tissues.
Nna E; Madukwe J; Egbujo E; Obiorah C; Okolie C; Echejoh G; Yahaya A; Adisa J; Uzoma I
Med Princ Pract; 2013; 22(2):138-43. PubMed ID: 23075505
[TBL] [Abstract][Full Text] [Related]
17. Novel Insight into Differential Gene Expression and Clinical Significance of Dopamine Receptors, COMT, and IL6 in BPH and Prostate Cancer.
Akbarian F; Abolhasani M; Dadkhah F; Asadi F; Ahangari G
Curr Mol Med; 2019; 19(8):605-619. PubMed ID: 31288722
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of N-myc downstream-regulated gene 2 in prostatic carcinoma.
Yu C; Wu G; Dang N; Zhang W; Zhang R; Yan W; Zhao Y; Gao L; Wang Y; Beckwith N; Yuan J; Yao L
Cancer Biol Ther; 2011 Aug; 12(4):304-13. PubMed ID: 21623166
[TBL] [Abstract][Full Text] [Related]
19. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues.
Zhao H; Ramos CF; Brooks JD; Peehl DM
J Cell Physiol; 2007 Jan; 210(1):111-21. PubMed ID: 17044071
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer.
Mengus C; Le Magnen C; Trella E; Yousef K; Bubendorf L; Provenzano M; Bachmann A; Heberer M; Spagnoli GC; Wyler S
J Transl Med; 2011 Sep; 9():162. PubMed ID: 21943235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
